Royce & Associates LP Has $12.97 Million Position in Organon & Co. (NYSE:OGN)

Royce & Associates LP lifted its stake in Organon & Co. (NYSE:OGN) by 23.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 869,394 shares of the company’s stock after purchasing an additional 166,300 shares during the quarter. Royce & Associates LP’s holdings in Organon & Co. were worth $12,971,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Pacer Advisors Inc. increased its holdings in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares in the last quarter. Geode Capital Management LLC grew its holdings in Organon & Co. by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after acquiring an additional 82,220 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Organon & Co. by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock worth $49,739,000 after acquiring an additional 10,652 shares during the period. Thompson Siegel & Walmsley LLC grew its holdings in Organon & Co. by 6.4% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock worth $43,279,000 after acquiring an additional 136,457 shares during the period. Finally, Private Management Group Inc. grew its holdings in Organon & Co. by 11.9% during the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock worth $31,620,000 after acquiring an additional 225,420 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on OGN. Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Morgan Stanley lowered their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Organon & Co. has an average rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Trading Up 2.1 %

Shares of NYSE OGN opened at $15.63 on Tuesday. The company’s fifty day moving average is $15.46 and its 200-day moving average is $16.60. The stock has a market cap of $4.03 billion, a price-to-earnings ratio of 4.69, a P/E/G ratio of 0.90 and a beta of 0.76. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.17%. Organon & Co.’s dividend payout ratio is currently 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.